Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.45 |
| ▸ | MMP1 | P03956 | 14/20 | 0.45 |
| ▸ | MMP3 | P08254 | 11/20 | 0.45 |
| ▸ | MMP7 | P09237 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 5/20 | 0.44 |
| ▸ | MMP8 | P22894 | 3/20 | 0.44 |
| ▸ | FCER2 | P06734 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27541796 | 1.00 | MMP2 (0.45) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL6898910 | 0.94 | MMP1 (0.46) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL27541579 | 0.91 | MME (0.48) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL6897823 | 0.91 | MME (0.48) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL6897211 | 0.88 | MMP1 (0.41) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL27559987 | 0.88 | MMP1 (0.41) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL6898127 | 0.88 | MMP1 (0.47) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL27543473 | 0.88 | MMP1 (0.47) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL6895549 | 0.86 | MMP1 (0.50) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL27541804 | 0.86 | MMP1 (0.50) | MMP2MMP1MMP3MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | MMP2 3359/4885MMP1 3883/4885MMP3 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.